Benefits Derivated From Late Steroid Withdrawal in Renal Transplant Recipients

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2173-2175

  Gavela, E ^a   Avila A ^a   Sancho, A ^a   Kanter, J ^a   Beltran S ^a   Crespo, J F ^a   Pallardo L M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; GLUCOSE; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GLUCAGON BLOOD LEVEL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR;

ADRENAL CORTEX HORMONES; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; RETROSPECTIVE STUDIES;

EID: 34548703354     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.027     Document Type: Article

References (12)

1. Veenstra D.L., Best J.H., Homberger J., et al. The incidence and long-term cost of steroid-related effects after renal transplantation. Am J Kidney Dis 33 (1999) 829
2. Pascual J., Quereda C., Zamora J., et al. Updated meta-analysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 37 (2005) 3746
3. Pascual J., Quereda C., Zamora J., et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 78 (2004) 1548
4. Kasiske B.L., Chakkera H.A., Louis T.A., et al. A meta-analysis of immunouppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11 (2000) 1910
5. Oriol B., Cruzado J.M., and Grinyó J.M. Corticosteroid-sparing strategies in renal transplantation. Are we still balancing rejection risk with improved tolerability. Drugs 66 (2006) 403
6. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.1 Long-term immunosuppression. Late steroid or cyclosporine withdrawal. Nephrol Dial Transplant 17 suppl 4 (2002) 19
7. Abramowicz D., Vanrenterghem Y., Squifflet J.P., et al. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Clin Transplant 19 (2005) 475
8. Metabolic effects of steroid avoidance or early steroid withdrawal: 12-month results of a randomized trial in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium and basiliximab. No authors listed. Transplantation 82 1 suppl 2 (2006) 483
9. Harada H., Miura M., Ogawa Y., et al. Late corticosteroid withdrawal can be safely performed for kidney recipients with stable graft function under pathological confirmation. Clin Transplant 20 suppl 15 (2006) 26
10. Rama I., Cruzado J.M., Gil-Vernet S., et al. Corticosteroids can be safely withdrawn from cyclosporine and mycophenolate mofetil treated renal allograft recipients: long-term results. Transplantation 80 (2005) 164
11. Loucaidou M., Borrows R., Cairns T., et al. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe. Transplant Proc 37 (2005) 1795
12. Anglicheau D., Flamant M., Schlageter M.H., et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 18 (2003) 2409